Mahmood Ladha

This profile gathers the share dealings of Mahmood Ladha in Swedish Orphan Biovitrum AB (publ). Over a trading history stretching from 9 June 2023 to 21 July 2026, the count stands at 19 filings.

The open-market side counts 5 purchases for €6.0M alongside 10 sales for €13.3M. Sales outweigh purchases by €7.3M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 4 share grants. Since January 2026: 1 purchase and 2 sales on the market.

Half of the purchases are above €1.3M and half below. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The newest entry dates from 21 July 2026: an open-market sale of €2.5M, in Swedish Orphan Biovitrum AB (publ). The last insider purchase was made public on 21 July 2026, 95 days ago. Filings reach the Finansinspektionen feed a median of 3 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.